Medicine application preparation for treating hypertension

A technology for high blood pressure and drugs, which is applied in the field of drug application preparations containing levamlodipine and angiotensin II receptor blockers, can solve the problems of no technical solutions for sustained release agents, and achieve benefits for high blood pressure Protection of target organ structure and function, improvement of remission, and reduction of impaired glucose tolerance

Inactive Publication Date: 2010-05-26
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patents CN1312715 and CN1733307 disclose a kind of pharmaceutical composition for the treatment or prevention of diabetes, hypertension accompanied by diabetes, and diabetic nephropathy, comprising valsartan and calcium channel blockers, but this invention only mentions the use of prior art to make this Pharmaceutical compositions made into tablets, capsules, suppositories
[0005] Chinese patent CN1883478 disc...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine application preparation for treating hypertension
  • Medicine application preparation for treating hypertension
  • Medicine application preparation for treating hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] The preparation of embodiment 1 sustained release tablet

[0035] Levoamlodipine Besylate 5g

[0036] Candesartan cilexetil 5g

[0037] Hydroxypropyl Methyl Cellulose 8g

[0038] Lactose 12g

[0039] Microcrystalline Cellulose 15g

[0040] 70% ethanol solution of 3% PVPk30 appropriate amount

[0041] Magnesium stearate 0.6g

[0042] Preparation Process:

[0043] First pass levamlodipine besylate and candesartan cilexetil through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and dextrin pass through an 80-mesh sieve.

[0044] Weigh levamlodipine besylate, candesartan cilexetil, hydroxypropyl methylcellulose, lactose, and microcrystalline cellulose according to the prescription amount, mix them evenly, and add 70% ethanol solution of 3% PVPk30 to prepare Soft material, passed through 18-mesh sieve to granulate, wet granule is dried at 50-60°C, dry granule is granulated through 16-mesh sieve, added magnesium stearate, mixed ev...

Embodiment 2

[0045] The preparation of embodiment 2 sustained-release tablets

[0046] Levoamlodipine Besylate 2.5g

[0047] Candesartan cilexetil 4g

[0048] Hydroxypropyl Methyl Cellulose 8g

[0049] Microcrystalline Cellulose 15g

[0050] Lactose 12g

[0051] 80% ethanol solution appropriate amount

[0052] Magnesium stearate 0.5g

[0053] Preparation Process:

[0054] First pass levamlodipine besylate and candesartan cilexetil through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and dextrin pass through an 80-mesh sieve.

[0055] Weigh levamlodipine besylate, candesartan cilexetil, hydroxypropyl methylcellulose, lactose, and microcrystalline cellulose according to the prescription amount, mix them evenly, and add 70% ethanol solution of 3% PVPk30 to prepare Soft material, passed through 18-mesh sieve to granulate, wet granule is dried at 50-60°C, dry granule is granulated through 16-mesh sieve, added magnesium stearate, mixed evenly, and ...

Embodiment 3

[0056] The preparation of embodiment 3 sustained-release tablets

[0057] Levoamlodipine Besylate 5g

[0058] Eprosartan Mesylate 600g

[0059]Hydroxypropyl Methyl Cellulose 750g

[0060] Lactose 120g

[0061] Microcrystalline Cellulose 450g

[0062] Starch 300g

[0063] 80% ethanol solution of 3% PVPk30 appropriate amount

[0064] Magnesium Stearate 5g

[0065] Preparation Process:

[0066] First pass levamlodipine besylate and eprosartan mesylate through a 100-mesh sieve; hydroxypropyl methylcellulose, microcrystalline cellulose, lactose, and starch pass through an 80-mesh sieve.

[0067] Weigh levamlodipine besylate, eprosartan mesylate, hydroxypropyl methylcellulose, lactose, microcrystalline cellulose and starch according to the prescription, mix them evenly, add 80% of 3% PVPk30 The ethanol solution is made of soft material, passed through a 18-mesh sieve to granulate, the wet granules are dried at 50-60°C, the dry granules are granulated through a 16-mesh sieve,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a slow/controlled release preparation of a medicine composition for treating hypertension. The slow/controlled release preparation composition contains levorotatory amlodipine and an angiotensin II receptor blocking agent which are in a specific proportion. Compared with a common preparation, the slow/controlled release preparation provided by the invention can enhance the effect of lowering the pressure, lower the pressure more stably, improve the insulin resistance of a patient more effectively and better prevent organ injuries caused by the hypertension.

Description

Technical field: [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a drug application preparation for treating hypertension containing two drug active ingredients, in particular to a drug application preparation containing levamlodipine and an angiotensin II receptor blocker. Background technique [0002] Hypertension is the most common cardiovascular disease and has become a major public health problem worldwide. According to statistics from the national health department, by the end of 2006, the number of hypertensive patients in my country had reached 160 million, and more than 3 million new patients were added every year. [0003] Hypertension is a syndrome with very complicated etiology and pathogenesis. Once diagnosed, it requires life-long medication. At present, domestic and foreign medical circles generally tend to use two antihypertensive drugs with different mechanisms of action in combination. According to the sixth report...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K9/48A61K45/06A61K31/4422A61P9/12A61K31/41A61K31/4178A61K31/4184
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap